Literature DB >> 24371200

Genome Sequence of a Novel, Newly Identified Isolate of Guinea Pig Cytomegalovirus, the CIDMTR Strain.

Mark R Schleiss1, Nelmary Hernandez-Alvarado, Thiruvarangan Ramaraj, John A Crow.   

Abstract

The sequence of a newly discovered isolate of guinea pig cytomegalovirus (GPCMV), the CIDMTR strain, was determined. The 232,778-nucleotide genome was generally well conserved with that of the 22122 reference strain, although some regions of substantial sequence divergence allowed annotation of strain-specific open reading frames encoding putative immune modulation gene products.

Entities:  

Year:  2013        PMID: 24371200      PMCID: PMC3873610          DOI: 10.1128/genomeA.01052-13

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Guinea pig cytomegalovirus (GPCMV) provides a useful model for congenital human cytomegalovirus (HCMV) infection (1, 2). GPCMV strain 22122, isolated by Hartley in 1957 (ATCC VR-682), has to date been the only strain available (3). This strain was sequenced using DNA purified both from tissue culture (TC)-passaged virus (4) and from guinea pig salivary gland (SG) homogenates following in vivo passage, with only minor differences noted (5). Some genomic instability of strain 22122 has been noted (6, 7), and its isolation and passage history are incompletely defined. Therefore, isolation of additional strains is desirable and would facilitate the modeling of HCMV reinfection, an emerging concern in women (8, 9). Commercially purchased Hartley strain guinea pigs were found to be GPCMV seropositive. A seropositive animal was immunosuppressed with cyclophosphamide, 100 mg/kg (10), and sacrificed 7 days later. SG homogenate was passaged in vivo in seronegative strain 2 guinea pigs. SG homogenates from these animals were then passaged on guinea pig fibroblasts, yielding plaques compatible with GPCMV. Following two additional passages in TC, virions were purified, and lysis buffer (200 mM NaCl, 2% SDS, and 200 µg/ml proteinase K in Tris-EDTA [TE]) was added. Following incubation at 68°C overnight, three phenol-chloroform extractions were performed, followed by ethanol precipitation of viral DNA. Genomic sequencing was performed using Illumina MiSeq and Pacific Biosciences (PacBio) RS platforms. Approximately 5.2 million 151-bp paired-end MiSeq reads were generated at the UMN Biomedical Genomics Center with a nominal insert size of 400 bp. Removal of low-quality reads and phiX sequences resulted in a set of 4.0 million cleaned reads, approximately 11,000× coverage. Scaffolds were generated from the cleaned Illumina reads using the ABySS assembler ver. 1.3.4 (11), and quality was assessed by mapping reads back to the assembly and manual comparison with KC503762 (5, 12). Special attention was paid to correct alignment and orientation of paired ends. Regions of weak coverage and scaffold gaps were identified and closed by manual local assembly (13) or by Sanger sequencing. Independent validation of the pseudomolecule was performed using the longer PacBio RS reads. Single-molecule real-time (SMRT) sequencing produced 998 high-quality (“corrected”) reads ranging between 509 and 15,898 bp, median 6,257 bp (~27× coverage), as well as another set of scaffolds. These data were used to evaluate the Illumina assembly, specifically its structural correctness, and to correct misassembled repeat regions. Comparison of the sequence with 22122 revealed a region of discrepancy spanning nucleotides ~198780 to 201300 of the CIDMTR sequence. A deletion of approximately 1.5 kb in this region resulted in the loss of a gp138 gene family member that was previously annotated in 22122 (5). A second region spanning coordinates 221540 through 224780 contained 1.45 kb of additional sequence that was not present in 22122, including a novel copy of a major histocompatibility complex (MHC) homolog, annotated as gp147.1 (14). Similar to HCMV, this region of the GPCMV genome appears prone to deletions, gene duplications, and rearrangements (15). Additional sequence analysis of wild-type strains may help resolve which sequence features represent the most authentic GPCMV genome.

Nucleotide sequence accession number.

The draft genome sequence for this strain has been deposited with the EMBL Nucleotide Sequence Database under the accession number HG531783. The CIDMTR strain of GPCMV has been deposited with the American Type Culture Collection (Manassas, VA) and is available from the corresponding author.
  15 in total

Review 1.  Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns.

Authors:  Mark R Schleiss
Journal:  ILAR J       Date:  2006

2.  The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs.

Authors:  Mark R Schleiss; David I Bernstein; Michael A McVoy; Greg Stroup; Fernando Bravo; Blaine Creasy; Alistair McGregor; Kristin Henninger; Sabine Hallenberger
Journal:  Antiviral Res       Date:  2005-01       Impact factor: 5.970

3.  Jalview Version 2--a multiple sequence alignment editor and analysis workbench.

Authors:  Andrew M Waterhouse; James B Procter; David M A Martin; Michèle Clamp; Geoffrey J Barton
Journal:  Bioinformatics       Date:  2009-01-16       Impact factor: 6.937

4.  Tablet--next generation sequence assembly visualization.

Authors:  Iain Milne; Micha Bayer; Linda Cardle; Paul Shaw; Gordon Stephen; Frank Wright; David Marshall
Journal:  Bioinformatics       Date:  2009-12-04       Impact factor: 6.937

5.  Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population.

Authors:  Aparecida Yulie Yamamoto; Marisa Marcia Mussi-Pinhata; Suresh B Boppana; Zdenek Novak; Virginia M Wagatsuma; Patricia de Frizzo Oliveira; Geraldo Duarte; William J Britt
Journal:  Am J Obstet Gynecol       Date:  2010-01-13       Impact factor: 8.661

6.  Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture.

Authors:  Naoki Nozawa; Yumiko Yamamoto; Yoshiko Fukui; Harutaka Katano; Yoshihiro Tsutsui; Yuko Sato; Souichi Yamada; Yuhki Inami; Kohnosuke Nakamura; Masayuki Yokoi; Ichiro Kurane; Naoki Inoue
Journal:  Virology       Date:  2008-07-24       Impact factor: 3.616

7.  Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread.

Authors:  Marcy Auerbach; Donghong Yan; Ashley Fouts; Min Xu; Alberto Estevez; Cary D Austin; Fernando Bazan; Becket Feierbach
Journal:  Virology       Date:  2013-04-04       Impact factor: 3.616

8.  Cytomegaloviral infections in the guinea pig: experimental models for human disease.

Authors:  F J Bia; B P Griffith; C K Fong; G D Hsiung
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

9.  Cytomegalovirus reinfections in healthy seroimmune women.

Authors:  Shannon A Ross; Nitin Arora; Zdenek Novak; Karen B Fowler; William J Britt; Suresh B Boppana
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

10.  Complete genome sequence of pathogenic Guinea pig cytomegalovirus from salivary gland homogenates of infected animals.

Authors:  Dongmei Yang; Kristen Tamburro; Dirk Dittmer; Xiaohong Cui; Michael A McVoy; Nelmary Hernandez-Alvarado; Mark R Schleiss
Journal:  Genome Announc       Date:  2013-03-14
View more
  2 in total

1.  Protection against Congenital CMV Infection Conferred by MVA-Vectored Subunit Vaccines Extends to a Second Pregnancy after Maternal Challenge with a Heterologous, Novel Strain Variant.

Authors:  Claudia Fernández-Alarcón; Grace Buchholz; Heidi Contreras; Felix Wussow; Jenny Nguyen; Don J Diamond; Mark R Schleiss
Journal:  Viruses       Date:  2021-12-20       Impact factor: 5.818

2.  Viral Glycoprotein Complex Formation, Essential Function and Immunogenicity in the Guinea Pig Model for Cytomegalovirus.

Authors:  Stewart Coleman; Julia Hornig; Sarah Maddux; K Yeon Choi; Alistair McGregor
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.